Drugs / OMEGA-3-PENTAENOIC ACIDS
OMEGA-3-PENTAENOIC ACIDS
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT02310022 | Nov 2014 → May 2015 | hypertriglyceridemia | Matinas Biopharma, Inc | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT04662528 | Jun 2021 → Aug 2022 | — | Matinas Biopharma, Inc | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2021-02-01 | Matinas BioPharma Nanotechnologies, Inc. | Results Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa® matinasbiopharma.com ↗
BEDMINSTER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, today announced topline results from the ENHANCE-IT study (Pharmacodynamic Effects of a Free-fatty Acid Formulation of Omega-3 Pentaenoic Acids to ENHANCE Efficacy in Adults with Hypertriglyceridemia), the second head-to-head comparative study of LYPDISO™ vs. Vascepa®. |
| 2021-01-04 | Matinas BioPharma Nanotechnologies, Inc. | Regulatory Matinas BioPharma Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001 matinasbiopharma.com ↗
today announced the U.S. Food and Drug Administration (FDA) has conditionally accepted LYPDISO™ as the proposed brand name for MAT9001, the Company’s investigational drug for treatment of cardiovascular and metabolic conditions. |
| 2015-06-15 | Matinas BioPharma Nanotechnologies, Inc. | Results Matinas BioPharma's MAT9001 Demonstrates Superiority in Reducing Triglycerides, Lipids, Apolipoproteins and PCSK9 Levels in Head-to-Head Study With Vascepa(R) matinasbiopharma.com ↗ |
| 2015-06-01 | Matinas BioPharma Nanotechnologies, Inc. | Results Matinas BioPharma's MAT9001 Meets Primary and Secondary Endpoints in First Human Trial versus Vascepa(R) matinasbiopharma.com ↗
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), a clinical-stage biopharmaceutical company, today announced top-line results for its head-to-head comparative pharmacokinetic and pharmacodynamic study versus Vascepa ® (icosapent ethyl). |
| 2014-12-23 | Matinas BioPharma Nanotechnologies, Inc. | Regulatory Matinas BioPharma Provides Update on Clinical Development Program for MAT9001 Following FDA Feedback on IND Submission matinasbiopharma.com ↗
The Company has received feedback from FDA on its IND submission for MAT9001. |
| 2014-10-29 | Matinas BioPharma Nanotechnologies, Inc. | Regulatory Matinas BioPharma Receives Authorization From Health Canada to Initiate Human Clinical Study of Lead Product Candidate MAT9001 matinasbiopharma.com ↗
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced that it has received a Notice of Authorization from Health Canada to initiate the first-in-human study of MAT9001 . |
| 2014-10-20 | Matinas BioPharma Nanotechnologies, Inc. | Regulatory Matinas BioPharma Submits Investigational New Drug Application for Lead Product Candidate MAT9001 for the Treatment of Severe Hypertriglyceridemia matinasbiopharma.com ↗
announced today that the Company has submitted an Investigational New Drug application (IND) for MAT9001 to the United States Food and Drug Administration (FDA). |
All press releases naming this drug 19 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OMEGA-3-PENTAENOIC ACIDS | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650221 ↗ |
| Known as | MAT9001 | “OBJECTIVE: To evaluate MAT9001, an investigational prescription-only omega-3 fatty acid agent containing predominantly eicosapentaenoic acid (EPA) and docosapentaenoic acid, in...” PMID 28391875 ↗ Oct 2016 |
| Known as | omega-3 pentaenoic acid | “MAT9001 (omega-3 pentaenoic acid)” NCT04662528 ↗ |
| Modality | Small molecule | — CHEMBL4650221 ↗ |